Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats

Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats

Zapnometinib is a MEK inhibitor currently under clinical development for the treatment of COVID-19 and influenza. Zapnometinib has both antiviral and immunomodulatory effects. Information concerning the absorption, distribution, metabolism, and excretion of the compound following single oral doses o...

Full description

Bibliographic Details
Main Authors:	Yvonne Füll, Christian Wallasch, Ashley Hilton, Oliver Planz
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Pharmacology
Subjects:	mek inhibitor absorption distribution metabolism excretion antiviral therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1050193/full

Similar Items

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
by: André Schreiber, et al.
Published: (2022-08-01)

Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs
by: Zainab Zakaraya, et al.
Published: (2024-02-01)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01)

The in vivo process of realgar from absorption to excretion
by: Yan Luo, et al.
Published: (2023-03-01)

Lycopene: A Critical Review of Digestion, Absorption, Metabolism, and Excretion
by: Joseph Arballo, et al.
Published: (2021-02-01)

Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2
by: Helen Hoffmann, et al.
Published: (2023-10-01)

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022-11-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
by: Lei He, et al.
Published: (2022-12-01)

Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development
by: Lara M. Schüssele, et al.
Published: (2022-12-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

PEDIATRIC LOW-GRADE GLIOMAS AND MEK INHIBITORS – CASE REPORT
by: Urša Jenko, et al.
Published: (2023-10-01)

Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
by: Giuseppe Fasolino, et al.
Published: (2023-02-01)

MEK inhibition and immune responses in advanced melanoma
by: Reinhard Dummer, et al.
Published: (2017-08-01)

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres
by: Eno I. Essien, et al.
Published: (2022-02-01)

Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature
by: Reinhard Büttner, et al.
Published: (2023-12-01)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
by: Bora Lim, et al.
Published: (2021-10-01)

A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1
by: OPhir Nave, et al.
Published: (2022-12-01)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
by: Emmanuelle M. Ruiz, et al.
Published: (2023-05-01)

Pharmacokinetics, bioavailability, and excretion of ponazuril in piglets
by: Wenxiang Wang, et al.
Published: (2022-12-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
by: Sonja C. S. Simon, et al.
Published: (2023-03-01)

Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
by: Luca Hegedüs, et al.
Published: (2021-02-01)

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
by: Francisco Meraz-Torres, et al.
Published: (2024-01-01)

Pharmacokinetics and Biological Activity of Cucurbitacins
by: Eugenia Elisa Delgado-Tiburcio, et al.
Published: (2022-10-01)

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
by: Jonathan N. Priantti, et al.
Published: (2023-07-01)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
by: Xi Yuan, et al.
Published: (2020-08-01)

Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers
by: Boya Li, et al.
Published: (2022-06-01)

Absorption, metabolism, and excretion of [14C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
by: Minoru Tsuda, et al.
Published: (2023-06-01)

Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
by: Michele Basilicata, et al.
Published: (2024-01-01)

Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence
by: Olga I. Butranova, et al.
Published: (2023-06-01)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
by: Yahong Liu, et al.
Published: (2023-09-01)

Tumor treatment with chemo-virotherapy and MEK inhibitor: A mathematical model of Caputo fractional differential operator
by: M. Moksud Alam, et al.
Published: (2023-05-01)

MEK inhibitors for the treatment of extracranial arteriovenous malformations
by: Zi’an Xu, et al.
Published: (2023-09-01)

Pharmacokinetics, Tissue Distribution and Excretion of Demethyleneberberine, a Metabolite of Berberine, in Rats and Mice
by: Jingqi Li, et al.
Published: (2023-11-01)

MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model
by: William E. Tidyman, et al.
Published: (2022-02-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
by: Amanda J. Unsworth, et al.
Published: (2019-08-01)